Physician profile
Daniel P Djondo
NPI 1285077453
$4,207.88
in general payments reported to CMS, 2019-2025
26 companies · $46.44 in 2025
The $46.44 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $126 · 2021: $308 · 2022: $1,095 · 2023: $1,286 · 2024: $446 · 2025: $46.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,778.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $703.12 | 2019 | |
| Genzyme Corporation | $699.54 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $648.90 | 2021-2024 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $423.79 | 2021-2024 | Dupixent |
| Glaxosmithkline, LLC. | $277.72 | 2022-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Electromed, INC. | $209.87 | 2021-2023 | Smartvest |
| United Therapeutics Corporation | $181.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.98 | 2022-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Intuitive Surgical, INC. | $155.05 | 2023-2025 | Da Vinci Surgical System |
| Genentech USA, INC. | $121.32 | 2019-2023 | Xolair |
| Erbe USA INC | $104.34 | 2020 | |
| Novartis Pharmaceuticals Corporation | $96.71 | 2022-2023 | |
| Amgen INC. | $77.41 | 2022-2024 | Tezspire |
| Baxter Healthcare | $55.74 | 2022-2023 | Hillrom - Visivest Airway Clearance System |
| Mylan Specialty L.P. | $37.94 | 2022-2024 | Yupelri |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $37.83 | 2023 | |
| Pinnacle Biologics, INC | $29.80 | 2024 | Photofrin |
| Inogen, INC. | $25.72 | 2022 | |
| Harmony Biosciences LLC | $24.44 | 2023 | Wakix |
| Nabriva Therapeutics, Plc | $22.32 | 2021 | |
| Advanced Respiratory, INC | $21.72 | 2020 | |
| Philips North America LLC | $19.74 | 2023 | |
| Grifols USA, LLC | $15.39 | 2023 | Prolastin-C Liquid |
| Insmed, INC. | $15.33 | 2025 | Brinsupri, Arikayce |
| Ambu INC. | $14.86 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Djondo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.